ConductScience.org, home

Paper2803953

Cisplatin/carboplatin cross-resistance in ovarian cancer.

Gore ME and 5 others. Br J Cancer, 1989. Cited by 106 papers, by iCite.

Cite this record

ConductScience Library. Cisplatin/carboplatin cross-resistance in ovarian cancer. Papers, record 2803953. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2803953

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cisplatin/carboplatin cross-resistance in ovarian cancer.
PubMed
Journal
Br J Cancer
PubMed
Year
1989
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
106
iCite
Relative citation ratio, by iCite
3.04
iCite
Revised in PubMed
2019-05-15
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gore MEM E
2Fryatt II
3Wiltshaw EE
4Dawson TT
5Robinson BAB A
6Calvert AHA H

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
CarcinomaMajor topic
CisplatinMajor topic
Ovarian NeoplasmsMajor topic
Adult
Drug Resistance
Female
Humans

Source PubMed

Download CSV of topics

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14038381Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.Cancer Res1985https://conductscience.org/library/papers/4038381PubMed
26315233Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.Cancer Treat Rep1983https://conductscience.org/library/papers/6315233PubMed
33910224Ovarian trials at the Royal Marsden.Cancer Treat Rev1985https://conductscience.org/library/papers/3910224PubMed
43512077
Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Cancer Res1986https://conductscience.org/library/papers/3512077PubMed
53517243A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma.J Clin Oncol1986https://conductscience.org/library/papers/3517243PubMed
63543243High-dose carboplatin in refractory ovarian cancer patients.J Clin Oncol1987https://conductscience.org/library/papers/3543243PubMed
72898306Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects.Carcinogenesis1988https://conductscience.org/library/papers/2898306PubMed
81000519Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary.Cancer Treat Rep1976https://conductscience.org/library/papers/1000519PubMed
9404216Second trial drugs in ovarian cancer.Gynecol Oncol1977https://conductscience.org/library/papers/404216PubMed
10350392Treatment of advanced ovarian cancer with cis=dichlorodiammineplatinum(II): poor-risk patients with intensive prior therapy.Cancer Treat Rep1978https://conductscience.org/library/papers/350392PubMed
11498148Rationale for development of platinum analogs.Cancer Treat Rep1979https://conductscience.org/library/papers/498148PubMed
12387224cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer.Cancer Treat Rep1979https://conductscience.org/library/papers/387224PubMed
137197985Use of high dose cis-dichlorodiammine platinum (II) (NSC--119875) following failure on previous chemotherapy for advanced carcinoma of the ovary.Br J Obstet Gynaecol1981https://conductscience.org/library/papers/7197985PubMed
146761010Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/6761010PubMed
152993535High-dose cisplatin in hypertonic saline in refractory ovarian cancer.J Clin Oncol1985https://conductscience.org/library/papers/2993535PubMed

Download CSV of references

Cited by34

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 106 citations.

PMIDTitleJournalYearIn PapersSource
39356625Resistance Management for Cancer: Lessons from Farmers.Cancer Res2024https://conductscience.org/library/papers/39356625PubMed
36499737Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives.Int J Mol Sci2022https://conductscience.org/library/papers/36499737PubMed
33076245Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.Int J Mol Sci2020https://conductscience.org/library/papers/33076245PubMed
32194363CRISPR/Cas9-mediated knockout of MLL5 enhances apoptotic effect of cisplatin in HeLa cells in vitro.EXCLI J2020https://conductscience.org/library/papers/32194363PubMed
32039434Structural insights into the promutagenic bypass of the major cisplatin-induced DNA lesion.Biochem J2020https://conductscience.org/library/papers/32039434PubMed
32022814Oxamusplatin: a cytotoxic Pt(ii) complex of a nitrogen mustard with resistance to thiol based sequestration displays enhanced selectivity towards cancer.Dalton Trans2020https://conductscience.org/library/papers/32022814PubMed
31174889A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.Gynecol Oncol2019https://conductscience.org/library/papers/31174889PubMed
30709915Structural basis for the bypass of the major oxaliplatin-DNA adducts by human DNA polymerase η.Biochem J2019https://conductscience.org/library/papers/30709915PubMed
29069808Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC.Oncotarget2017https://conductscience.org/library/papers/29069808PubMed
25444929Tyrosine phosphorylation of HSC70 and its interaction with RFC mediates methotrexate resistance in murine L1210 leukemia cells.Cancer Lett2015https://conductscience.org/library/papers/25444929PubMed
24874729Systems biology of cisplatin resistance: past, present and future.Cell Death Dis2014https://conductscience.org/library/papers/24874729PubMed
24155778UCHL1 Is a Putative Tumor Suppressor in Ovarian Cancer Cells and Contributes to Cisplatin Resistance.J Cancer2013https://conductscience.org/library/papers/24155778PubMed
23349823Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.PLoS One2013https://conductscience.org/library/papers/23349823PubMed
19688066
Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer.
Cancer Res Treat2009https://conductscience.org/library/papers/19688066PubMed
14576837Cisplatin: mode of cytotoxic action and molecular basis of resistance.Oncogene2003https://conductscience.org/library/papers/14576837PubMed
11085200Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.Drugs2000https://conductscience.org/library/papers/11085200PubMed
9649119Anti-proliferative activity and mechanism of action of titanocene dichloride.Br J Cancer1998https://conductscience.org/library/papers/9649119PubMed
9092638Effect of geometric isomerism in dinuclear platinum antitumour complexes on the rate of formation and structure of intrastrand adducts with oligonucleotides.Nucleic Acids Res1997https://conductscience.org/library/papers/9092638PubMed
8980393The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study.Br J Cancer1996https://conductscience.org/library/papers/8980393PubMed
8573296Comparative adverse effect profiles of platinum drugs.Drug Saf1995https://conductscience.org/library/papers/8573296PubMed

See all 34 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2803953

GET https://conductscience.org/api/papers/v1/2803953/cited_by?page=2